Pediatric palliative care is a specialized medical care for infants and children living with serious medical conditions such as cancer, genetic disorders, prematurity, heart and lung conditions, neurologic disorders, and others. The goal of palliative care is to improve quality of life for both the child and the family by providing relief from the symptoms and stress of the illness.
Various drugs provided in the palliative care include analgesics, antiemetic, laxatives, adjuvant medications, steroids, sedatives, neuroleptic medications, and others.
The global pediatric palliative care drugs market is estimated to be valued at US$ 71.8 billion in 2020 and is expected to exhibit a CAGR of 5.1% over the forecast period (2020-2027).
Figure 1. Global Pediatric Palliative Care Drugs Market Share (%) in Terms of Value, By Region, 2020
Increasing number of rare diseases with pediatric onset is expected to propel the market growth over the forecast period
Increasing number of rare genetic diseases which have pediatric onset leads to an increased demand for pediatric palliative care drugs, which is expected to drive the market growth over the forecast period. According to an article published in the European Journal of Human Genetics in September 2019, out of 6,172 clinically unique rare diseases described in Orphanet, an international reference knowledge base for rare diseases and orphan drugs, around 3,510 (69.9%) diseases are exclusively pediatric onset and around 908 (18.2%) diseases have onset spanning both adults and pediatric groups.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 71.8 Bn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 5.1% | 2027 Value Projection: | US$ 101.8 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Novartis International AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Anqiu Lu'an Pharmaceutical Co., Ltd., Granules India Limited, Zhejiang Kangle Pharmaceutical Co., Ltd., Farmson Pharmaceutical Gujarat Pvt. Ltd., Atabay Pharmaceutical Factory, Anhui Fubore Pharmaceutical & Chemical Co., Ltd, Huzhou Konch Pharmaceutical Co., Ltd., Alnylam Pharmaceuticals Inc., Eton Pharmaceuticals, Inc, and Eisai Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Increasing pediatric drugs product approvals by regulatory authorities is expected to drive the market growth over the forecast period
Market players are more focused on obtaining product approvals from regulatory authorities in order to expand their product portfolio in pediatric palliative care drugs market, which is expected to boost the market growth over the forecast period. For instance, in August 2018, Eisai Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug, FYCOMPA, indicated for monotherapy and adjunctive use in patients of age 4 years and older for treating partial-onset seizures (POS). Eisai Inc. received approval from the U.S. FDA for both tablet and oral suspension formulations of FYCOMPA.
Global Pediatric Palliative Care Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
The coronavirus disease (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020.
According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 34.8 million cases and more than 1 million deaths due to coronavirus disease (COVID-19) were reported on October 04, 2020 across the globe.
According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the coronavirus disease (COVID-19) cases in different regions reported on October 04, 2020 are as follows:
|
WHO Regions |
New cases in last 7 days |
Cumulative cases |
|
The Americas |
756,926 |
16,990,036 |
|
South-east Asia |
614,502 |
7,335,273 |
|
Europe |
478,119 |
6,187,384 |
|
Africa |
26,208 |
1,198,550 |
|
Eastern Mediterranean |
125,567 |
2,466,722 |
|
Western Pacific |
24,751 |
625,642 |
COVID-19 has affected the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of products and raw materials from one place to another, which is expected to limit the market growth during the forecast period.
Pediatric Palliative Care Drugs Market: Restraints
However, lack of awareness about palliative care is expected to hinder growth of the global pediatric palliative care drugs market during the forecast period. According to the New Public Opinion Research from the Center to Advance Palliative Care (CAPC), August 2019, palliative care is relatively unknown among general public but with proper education about the palliative care, understanding and favorability might increase among consumers and physicians.
Key Players
Major players operating in the global pediatric palliative care drugs market include Novartis International AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Anqiu Lu'an Pharmaceutical Co., Ltd., Granules India Limited, Zhejiang Kangle Pharmaceutical Co., Ltd., Farmson Pharmaceutical Gujarat Pvt. Ltd., Atabay Pharmaceutical Factory, Anhui Fubore Pharmaceutical & Chemical Co., Ltd, Huzhou Konch Pharmaceutical Co., Ltd., Alnylam Pharmaceuticals Inc., Eton Pharmaceuticals, Inc, and Eisai Inc.
Palliative care focuses on improving the quality of life of people who are suffering from chronic diseases such as kidney failure, amyotrophic lateral sclerosis (ALS), cancer, Parkinson’s, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), and others. Therefore, increasing prevalence of such diseases, especially cancer, is expected to drive growth of the pediatric palliative care drugs market over the forecast period. According to the Cancer Research UK, around 1,878 new cases of cancer in children were diagnosed from 2015 to 2017 in the U.K.
Market Dynamics
Market players are focusing on adopting various inorganic growth strategies such as acquisitions and agreements in order to enhance their product portfolio for rare and genetic diseases such as congenital adrenal hyperplasia (CAH) and strengthen their market presence. For instance, on March 27, 2020, Eton Pharmaceuticals, Inc, a pharmaceutical company, which focuses on development and commercialization of innovative drug products, announced the acquisition of the U.S. marketing rights for Alkindi Sprinkle, a neutral sprinkle (granule) formulation of hydrocortisone, developed by Diurnal Group plc, a U.K.-based pharmaceutical company. Alkindi Sprinkle is a replacement therapy for pediatric adrenal insufficiency (AI), including the genetic disorder congenital adrenal hyperplasia (CAH).
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients